Camrelizumab: First Global Approval

被引：284
作者：
Markham, Anthony [1 ]
Keam, Susan J. [1 ]
机构：
[1] Springer Nat, Private Bag 65901, Auckland 0754, New Zealand
来源：
DRUGS | 2019年 / 79卷 / 12期
关键词：
D O I：
10.1007/s40265-019-01167-0
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Camrelizumab (AiRuiKa (TM)), a programmed cell death 1 (PD-1) inhibitor being developed by Jiangsu Hengrui Medicine Co. Ltd, recently received conditional approval in China for the treatment of relapsed or refractory classical Hodgkin lymphoma. The drug is also being investigated as a treatment for various other malignancies, including B cell lymphoma, oesophageal squamous cell carcinoma, gastric/gastroesophageal junction cancer, hepatocellular carcinoma, nasopharyngeal cancer and non-squamous, non-small cell lung cancer. This article summarizes the milestones in the development of camrelizumab leading to this first approval for classical Hodgkin lymphoma.
引用
收藏
页码：1355 / 1361
页数：7
相关论文
共 19 条
  • [1] PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome
    Alsaab, Hashem O.
    Sau, Samaresh
    Alzhrani, Rami
    Tatiparti, Katyayani
    Bhise, Ketki
    Kashaw, Sushil K.
    Iyer, Arun K.
    [J]. FRONTIERS IN PHARMACOLOGY, 2017, 8
  • [2] [Anonymous], 2019, DATA FILE JIANGSU HE
  • [3] Reactive capillary hemangiomas: a novel dermatologic toxicity following anti-PD-1 treatment with SHR-1210
    Chen, Xuelian
    Ma, Lanying
    Wang, Xi
    Mo, Hongnan
    Wu, Dawei
    Lan, Bo
    Qu, Dong
    Zhang, Hongtu
    Huang, Jing
    Xu, Binghe
    [J]. CANCER BIOLOGY & MEDICINE, 2019, 16 (01) : 173 - +
  • [4] Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials
    Fang, Wenfeng
    Yang, Yunpeng
    Ma, Yuxiang
    Hong, Shaodong
    Lin, Lizhu
    He, Xiaohui
    Xiong, Jianping
    Li, Ping
    Zhao, Hongyun
    Huang, Yan
    Zhang, Yang
    Chen, Likun
    Zhou, Ningning
    Zhao, Yuanyuan
    Hou, Xue
    Yang, Qing
    Zhang, Li
    [J]. LANCET ONCOLOGY, 2018, 19 (10) : 1338 - 1350
  • [5] Promising efficacy of SHR-1210, a novel anti-programmed cell death 1 antibody, in patients with advanced gastric and gastroesophageal junction cancer in China
    Huang, Jing
    Mo, Hongnan
    Zhang, Weilong
    Chen, Xuelian
    Qu, Dong
    Wang, Xi
    Wu, Dawei
    Wang, Xingyuan
    Lan, Bo
    Yang, Beibei
    Wang, Pei
    Zhang, Bo
    Yang, Qing
    Jiao, Yuchen
    Xu, Binghe
    [J]. CANCER, 2019, 125 (05) : 742 - 749
  • [6] Safety, Activity, and Biomarkers of SHR-1210, an Anti-PD-1 Antibody, for Patients with Advanced Esophageal Carcinoma
    Huang, Jing
    Xu, Binghe
    Mo, Hongnan
    Zhang, Weilong
    Chen, Xuelian
    Wu, Dawei
    Qu, Dong
    Wang, Xingyuan
    Lan, Bo
    Yang, Beibei
    Wang, Pei
    Zhang, Hongtu
    Yang, Qing
    Jiao, Yuchen
    [J]. CLINICAL CANCER RESEARCH, 2018, 24 (06) : 1296 - 1304
  • [7] Incyte Corporation, 2018, FORM 10 Q Q REP Q PE
  • [8] Jiangsu Hengrui Medicine Co. Ltd, 2019, CAMR CHIN PRESCR INF
  • [9] Combination of Radiation Therapy and Anti-PD-1 Antibody SHR-1210 in Treating Patients with Esophageal Squamous Cell Cancer
    Jing, Z.
    Du, D.
    Zhang, N.
    Dai, H.
    Wang, X.
    Hua, Y.
    Jiang, M.
    Wu, S.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 102 (03): : E31 - E31
  • [10] Safety, anti-tumour activity, and pharmacokinetics of fixed- dose SHR-1210, an anti-PD-1 antibody in advanced solid tumours: a dose-escalation, phase 1 study
    Mo, Hongnan
    Huang, Jing
    Xu, Jiachen
    Chen, Xuelian
    Wu, Dawei
    Qu, Dong
    Wang, Xi
    Lan, Bo
    Wang, Xingyuan
    Xu, Jianping
    Zhang, Honggang
    Chi, Yihebali
    Yang, Qing
    Xu, Binghe
    [J]. BRITISH JOURNAL OF CANCER, 2018, 119 (05) : 538 - 545
12